Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06579105
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-28
Brief Title:
Efficacy Safety and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase IIb Randomized Double-blind Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SOLSTICE
Brief Summary:
This is a Phase IIb randomised double-blind parallel-group placebo-controlled study to evaluate the efficacy safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus compared to placebo and active comparator
Detailed Description:
This is a Phase IIb randomised double-blind parallel-group placebo-controlled study to evaluate the efficacy safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus compared to placebo and active comparator The study is planned to be conducted in approximately 15 countries approximately 90 sites will be involved
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None